Medtronic’s Anti-Bacterial Implantable Device Envelope Proves Cost-Effective In Study
A new analysis of the WRAP IT study shows the Tyrx absorbable antibacterial envelope is a cost-effective tool for preventing infections around cardiac implantable electronic devices.
You may also be interested in...
Start-Up Spotlight: Resonant Link Plans To Electrify Device Industry With Efficient Wireless Charging Technology
The company is commercializing technology developed at Dartmouth and Stanford universities, hoping that its technology will reduce the size and complication rates of implantable devices.
Medtronic’s revenue of $6.5bn in the first quarter of fiscal 2021 represents a 17% fall year-over-year, but it still beat analysts’ projections.
ACC Results Recap Part II: CardioMEMS Post-Approval Trial Shows Monitoring Reduces Heart-Failure Hospitalizations; Medtronic’s Tyrx Envelope Reduces Infections
Medtech Insight's Results Recap is a regular feature covering the major device trial results compiled by MedDeviceTracker. This is the second of three Results Recaps covering trial data presented at the American College of Cardiology Scientific Sessions in New Orleans, March 16-18, including clinical trial data on devices from Abbott Laboratories, Medtronic, Medi-Lynx, and iRhythm. See Part 1 of our ACC Results Recap for more on the groundbreaking trials of transcatheter aortic valve replacement in low-risk patients and the Apple Heart study of Apple Watch's ability to track atrial fibrillation.